Modeling <i>IKZF1</i> lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilitiesJason H. Rogers, Rachel E. Rau|Blood Advances|2021Cited by 10
Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell ClonesKatharina Wohlan, Margaret A. Goodell, Meghan Kisiel et al.|Blood|2022Cited by 1